Literature DB >> 20061905

More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

Jose S Pulido, Jose E Pulido, Clement J Michet, Richard G Vile.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20061905      PMCID： PMC3893927          DOI： 10.1097/IAE.0b013e3181cde727

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  37 in total

1.  Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease.

Authors:  P P Sfikakis; P H Kaklamanis; A Elezoglou; N Katsilambros; P G Theodossiadis; S Papaefthimiou; N Markomichelakis
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

2.  Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab.

Authors:  Petros P Sfikakis; Nikos Markomichelakis; George P Theodossiadis; Vlassis Grigoropoulos; Nikos Katsilambros; Panayiotis G Theodossiadis
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

3.  Adverse events after intravitreal infliximab (Remicade).

Authors:  Monica Giganti; Paul M Beer; Nicole Lemanski; Coby Hartman; Jerome Schartman; Naomi Falk
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

Review 4.  Immunogenicity of engineered antibodies.

Authors:  William Ying Khee Hwang; Jefferson Foote
Journal:  Methods       Date:  2005-05       Impact factor: 3.608

5.  Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Authors:  P P Sfikakis; P G Theodossiadis; C G Katsiari; P Kaklamanis; N N Markomichelakis
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

6.  Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus.

Authors:  J M González-Clemente; D Mauricio; C Richart; M Broch; A Caixàs; A Megia; O Giménez-Palop; I Simón; A Martínez-Riquelme; G Giménez-Pérez; J Vendrell
Journal:  Clin Endocrinol (Oxf)       Date:  2005-11       Impact factor: 3.478

7.  Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Authors:  Gennady Landa; Wendewessen Amde; Vatsal Doshi; Amro Ali; Laura McGevna; Ronald C Gentile; Thomas O Muldoon; Joseph B Walsh; Richard B Rosen
Journal:  Ophthalmologica       Date:  2009-07-08       Impact factor: 3.250

8.  Infliximab for chronic cystoid macular edema associated with uveitis.

Authors:  Nikos N Markomichelakis; Panagiotis G Theodossiadis; Eygenia Pantelia; Semina Papaefthimiou; George P Theodossiadis; Petros P Sfikakis
Journal:  Am J Ophthalmol       Date:  2004-10       Impact factor: 5.258

Review 9.  Molecular differences in anticytokine therapies.

Authors:  L H Calabrese
Journal:  Clin Exp Rheumatol       Date:  2003 Mar-Apr       Impact factor: 4.473

10.  Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.

Authors:  Shigeaki Ohno; Satoshi Nakamura; Sadao Hori; Machiko Shimakawa; Hidetoshi Kawashima; Manabu Mochizuki; Sunao Sugita; Satoki Ueno; Kazuyuki Yoshizaki; Goro Inaba
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666
View more
  9 in total

Review 1.  Ocular vasculitis.

Authors:  Gabriela M Espinoza; Ankit Desai; Levent Akduman
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

Review 2.  Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders.

Authors:  Isabel Pascual-Camps; Pablo Hernández-Martínez; Laura Monje-Fernández; Rosa Dolz-Marco; Roberto Gallego-Pinazo; Lihteh Wu; J Fernando Arévalo; Manuel Díaz-Llopis
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-10-15

Review 3.  Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.

Authors:  Steven Yeh; Thomas A Albini; Andrew A Moshfeghi; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2012-09       Impact factor: 5.258

Review 4.  New options for uveitis treatment.

Authors:  Yu He; Song-Bai Jia; Wei Zhang; Jing-Ming Shi
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

5.  Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts.

Authors:  Alireza Mirshahi; René Hoehn; Katrin Lorenz; Christina Kramann; Holger Baatz
Journal:  J Ophthalmic Vis Res       Date:  2012-01

6.  Local therapies for inflammatory eye disease in translation: past, present and future.

Authors:  Shenzhen Tempest-Roe; Lavnish Joshi; Andrew D Dick; Simon R J Taylor
Journal:  BMC Ophthalmol       Date:  2013-08-06       Impact factor: 2.209

7.  Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy.

Authors:  Hui Hang; Songtao Yuan; Qin Yang; Dongqing Yuan; Qinghuai Liu
Journal:  Mol Vis       Date:  2014-08-04       Impact factor: 2.367

Review 8.  Birdshot uveitis: current and emerging treatment options.

Authors:  Victor Menezo; Simon Rj Taylor
Journal:  Clin Ophthalmol       Date:  2013-12-18

Review 9.  Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye.

Authors:  Michael Mikhail; Ahmed Sallam
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.